CATALYST PHARMACEUTICALS, INC. Stockholders Equity

Quick Answer

CATALYST PHARMACEUTICALS, INC. reported Stockholders Equity of $954.27 million for the year ending 2025.

  • CATALYST PHARMACEUTICALS, INC. showed an increase of +31.1% in Stockholders Equity from 2024 to 2025.
  • This data is from CATALYST PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
  • XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Quarterly values from 10-Q filings: Q1 2014: $17.64 million | Q2 2014: $41.19 million | Q3 2014: $36.62 million | Q1 2015: $66.62 million | Q2 2015: $62.79 million | Q3 2015: $60.65 million | Q1 2016: $50.54 million | Q2 2016: $46.33 million | Q3 2016: $42.90 million | Q1 2017: $35.10 million | Q2 2017: $33.97 million | Q3 2017: $31.73 million | Q1 2018: $76.25 million | Q2 2018: $71.06 million | Q3 2018: $64.08 million | Q1 2019: $51.18 million | Q2 2019: $63.28 million | Q3 2019: $77.98 million | Q1 2020: $99.68 million | Q2 2020: $111.20 million | Q3 2020: $156.63 million | Q1 2021: $178.65 million | Q2 2021: $188.94 million | Q3 2021: $198.66 million | Q1 2022: $220.22 million | Q2 2022: $241.09 million | Q3 2022: $270.04 million | Q1 2023: $333.66 million | Q2 2023: $375.29 million | Q3 2023: $348.55 million | Q1 2024: $561.41 million | Q2 2024: $608.66 million | Q3 2024: $660.94 million | Q1 2025: $794.28 million | Q2 2025: $856.03 million | Q3 2025: $920.25 million.
  • Over the full 15 years of available data (2011 to 2025), CATALYST PHARMACEUTICALS, INC.'s Stockholders Equity has grown by 25,274.8%.
  • Historical annual values: Fiscal year 2025: $954.27 million | Fiscal year 2024: $727.63 million | Fiscal year 2023: $387.88 million | Fiscal year 2022: $300.42 million | Fiscal year 2021: $206.83 million | Fiscal year 2020: $169.60 million | Fiscal year 2019: $87.63 million | Fiscal year 2018: $50.79 million | Fiscal year 2017: $80.96 million | Fiscal year 2016: $39.31 million | Fiscal year 2015: $55.48 million | Fiscal year 2014: $35.24 million | Fiscal year 2013: $21.39 million | Fiscal year 2012: $14.62 million | Fiscal year 2011: $3.76 million.
  • Data sourced from SEC EDGAR public filings as of August 6, 2026.

Last verified: